

References

1. Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. *J Am Coll Cardiol*. 2012; 59:991–997.
2. Jeroudi OM, Alomar ME, Michael TT, et al. Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. *Catheter Cardiovasc Interv*. 2014; 84:637–643.
3. Stone GW, Kandzari DE, Mehran R, Colombo A, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. *Circulation*. 2005; 112:2364–2372.
4. Cohen HA, Williams DO, Holmes DR, et al. Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry. *Am Heart J*. 2003 Sep;146(3):513-9.
5. Godino C, Sharp AS, Carlino M, Colombo A. Crossing CTOs-the tips, tricks, and specialist kit that can mean the difference between success and failure. *Catheter Cardiovasc Interv*. 2009; 74: 1019–46.
6. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. *J Am Coll Cardiol*. 2009 Jan 27;53(4):323-30.
7. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. *Circulation*. 1998 Sep 22;98(12):1164-71.
8. Ammirati, E., Moroni, F., Magnoni, M., et al. Circulating CD14+ and CD14 high CD16– classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. *Atherosclerosis*, 2016; 255, 171–178.

9. Aukrust, P., Halvorsen, B., Yndestad, A., et al. Chemokines and cardiovascular risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2008; 28(11), 1909–1919.
10. Tani, S., Matsumoto, M., Anazawa, T., et al. Development of a model for prediction of coronary atherosclerotic regression: Evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count. *Heart and Vessels*. 2012; 27(2), 143–150.
11. Acikgoz, N., Kurtoğlu, E., Yagmur, J., Kapicioglu, Y., Cansel, M., & Ermis, N. Elevated monocyte to high-density lipoprotein cholesterol ratio and endothelial dysfunction in behçet disease. *Angiology*. 2017; 69(1), 65–70.
12. Ganjali, S., Momtazi, A. A., Banach, M., Kovanen, P. T., Stein, E. A., & Sahebkar, A. HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. *Progress in Lipid Research*. 2017; 67, 16–26.
13. Gomaschi, M., Basilico, N., Sisto, F., Taramelli, D., Eligini, S., Colli, S., Calabresi, L. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. *Biochimica et Biophysica Acta*. 2005; 1736(2), 136–143.
14. Cetin EH, Cetin MS, Canpolat U et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *Biomark. Med.* 2015; 9(10), 967–977.
15. Fan Z, Ji H, Li Y, Jian X, Li L, Liu T. Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina. *Biomark. Med.* 2017; 11(11), 979–990.
16. Canpolat U, Aytemir K, Yorgun H et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. *Europace*. 2015; 17(12), 1807–1815.

17. Kundi H, Gok M, Kiziltunc E et al. Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. *Am. J. Cardiol.* 2015; 116(11), 1685–1689.
18. Canpolat U, Cetin EH, Cetin S et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. *Clin. Appl. Thromb. Hemost.* 2016; 22(5), 476–482.
19. Demir V, Samet Y, Akboga MK. Association of lymphocyte-monocyte ratio and monocyte-to-high-density lipoprotein ratio with the presence and severity of rheumatic mitral valve stenosis. *Biomark. Med.* 2017; 11(8), 657–663.
20. Ekizler FA, Cay S, Açar B, et al. Monocyte to high-density lipoprotein cholesterol ratio predicts adverse cardiac events in patients with hypertrophic cardiomyopathy. *Biomark Med.* 2019;13(14):1175-1186.
21. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. *Circulation.* 2006 May 23;113(20):2406-12.
22. Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. *JACC Cardiovasc Interv.* 2009 Jan;2(1):17-25.
23. Surya, I.K.R., et al., High Ratio of Monosit: High-Density Lipoprotein as a Risk Factor Of chronic Total Occlusion in Patients Coronary Artery Disease. *Asian Journal of Pharmaceutical and Clinical Research.* 2020; p. 155-158.
24. Bolayir A, Gokce SF, Cigdem B, et al. Monocyte/high-density lipoprotein ratio predicts the mortality in ischemic stroke patients. *Neurol Neurochir Pol.* 2018 Mar;52(2):150-155.
25. Efe T , Arslan E , Ertem A , et al. Akut Pulmoner Emboli Hastalarında Monosit/HDL Oranının Kısa Dönem Mortaliteyi Ön Gördürmedeki Prognostik Değeri. *Koşuyolu Heart Journal.* 2016; 149-153.

26. Wu, TT., Zheng, YY., Chen, Y. et al. Monocyte to high-density lipoprotein cholesterol ratio as long-term prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention. *Lipids Health Dis.* 2019; 18, 180.
27. Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ. The anti inflammatory effects of high density lipoproteins. *Curr Med Chem.* 2009; 16:667-75.
28. Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. *Clin Exp Pharmacol Physiol.* 2010; 37:710-8.
29. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. *Science.* 2010; 328:1689-93.
30. Wrigley BJ, Shantsila E, Tapp LD, Lip GY. CD14⁺⁺CD16⁺ monocytes in patients with acute ischaemic heart failure. *Eur J Clin Invest.* 2013 Feb;43(2):121-30.
31. Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. *J Heart Lung Transplant.* 2009 Sep;28(9):876-80.